Biogen Idec commissioned Charles River Associates to examine how access to innovative treatments for multiple sclerosis (MS) varies across European countries, the factors explaining this, and the policy lessons that can be drawn. MS is a disorder of the central nervous system (brain and spinal cord) affecting over 500,000 Europeans. CRA found that significant inequalities in access to MS treatments persist in 2013. To download the PDF version of this report click the link below.
What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...